GSDMD also has been confirmed as a key regulator and a therapeutic target in several diseases, like multiple sclerosis (MS), experimental autoimmune encephalomyelitis (EAE) (23, 24), cryopyrin-associated periodic syndromes (CAPS) (25–27), and Gram-negative bacteria–induced sepsis (6, 28, 29). Here, GSDMD is linked to cryopyrin-associated periodic syndrome.